Article
Biochemistry & Molecular Biology
Long Teng, Tuchen Guan, Beibei Guo, Chao Ma, Ge Lin, Ronghua Wu, Man Xu, Mei Liu, Yan Liu
Summary: This study established an in vitro model to screen for genes involved in neurite outgrowth, and found that the GIP-GIPR axis can promote axonal outgrowth; the results showed that GIP significantly improved extension of axon.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Taisuke Yamauchi, Megumi Miyabe, Nobuhisa Nakamura, Mizuho Ito, Takeo Sekiya, Saki Kanada, Rina Hoshino, Tatsuaki Matsubara, Ken Miyazawa, Shigemi Goto, Keiko Naruse
Summary: This study investigated the effects of glucose-dependent insulinotropic polypeptide (GIP) on force-induced bone remodeling during orthodontic tooth movement. The results suggest that GIP promotes osteoblast formation and suppresses osteoclasts in force-induced bone remodeling.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Nadya M. Morrow, Antonio A. Hanson, Erin E. Mulvihill
Summary: Enteroendocrine cells play a crucial role in regulating nutrient intake and disposal through the production and secretion of peptides. Understanding the identity of cells expressing Glp1r, Glp2r, and Gipr in different models can provide insights into dysregulation seen in obesity and diabetes. Further research on G-protein coupled receptor circuits in the intestine and their alterations with high-fat diet feeding is also important in understanding metabolic diseases.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Geke Aline Boer, Jenna Elizabeth Hunt, Maria Buur Nordskov Gabe, Johanne Agerlin Windelov, Alexander Hovard Sparre-Ulrich, Bolette Hartmann, Jens Juul Holst, Mette Marie Rosenkilde
Summary: This study investigated the characteristics of the GIP antagonist mGIPAnt-1, and found that it has antagonistic properties both in vitro and in vivo, and effectively inhibits high-fat diet-induced weight gain in ovariectomised mice. This provides a new research direction for the treatment of obesity.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Review
Immunology
Gaber El-Saber Batiha, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nada A. Ashour, Walaa A. Negm
Summary: In Covid-19 patients, variations in fasting blood glucose are considered a distinct risk factor for a negative prognosis. Tirazepatide (TZT), a dual GLP-1 and GIP receptor agonist, may be effective in managing Covid-19-induced hyperglycemia in both diabetic and non-diabetic patients.
INFLAMMOPHARMACOLOGY
(2023)
Article
Endocrinology & Metabolism
Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Soren Toubro, Sune Boris Nygard
Summary: NNC9204-1177 (NN1177) is a glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonist used for weight loss treatment. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of NN1177 through three phase 1 trials. While NN1177 showed some efficacy in weight loss, it also presented several treatment-related safety signals.
MOLECULAR METABOLISM
(2023)
Article
Endocrinology & Metabolism
Olof Eriksson, Irina Velikyan, Torsten Haack, Martin Bossart, Andreas Evers, Katrin Lorenz, Iina Laitinen, Philip J. Larsen, Oliver Plettenburg, Lars Johansson, Stefan Pierrou, Michael Wagner
Summary: The study successfully developed a novel PET biomarker [Ga-68]S02-GIP-T4 for safe, noninvasive, and quantitative assessment of GIPR target distribution and drug occupancy. The PET tracer showed high affinity and specificity to huGIPR in overexpressing cells, allowing for effective prediction of drug candidate binding and occupancy in NHPs.
Article
Endocrinology & Metabolism
Gemma Pujadas, Laurie L. Baggio, Kiran Deep Kaur, Brent A. McLean, Xiemin Cao, Daniel J. Drucker
Summary: The loss of GIPR signaling in mice leads to increased aortic atherosclerosis and enhanced inflammation in the aorta and liver, despite reduced weight gain and preserved glucose homeostasis. These findings indicate that GIPR has a broader role in suppressing inflammation-related pathophysiology beyond its classical incretin role in metabolic control.
MOLECULAR METABOLISM
(2022)
Article
Multidisciplinary Sciences
Tsuguto Masaki, Yoshio Kodera, Michishige Terasaki, Kazumi Fujimoto, Tsutomu Hirano, Masayoshi Shichiri
Summary: A new plasma peptidomic technique was used to identify a novel endogenous proatherogenic peptide, GIP_HUMAN[22-51], which accelerates atherosclerosis by modulating the cardiovascular system and inducing inflammatory responses.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Soyeon Yoo, Dongkyu Kim, Gwanpyo Koh
Summary: The study investigated changes in glucagon levels in people with diabetes after meal ingestion, finding that poorly controlled patients may have a greater increase in postprandial glucagon levels, which is not mediated by incretin.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Florent X. Smit, Wijnand J. C. van der Velden, Husun S. Kizilkaya, Amalie Norskov, Michael Luckmann, Tobias N. Hansen, Alexander H. Sparre-Ulrich, Katrine Qvotrup, Thomas M. Frimurer, Mette M. Rosenkilde
Summary: The study investigates the structure and function of the GIP receptor (GIPR) and identifies key residues involved in ligand binding and receptor activation. The findings suggest that disrupting a specific salt bridge by GIPR antagonists can significantly reduce GIPR activation, providing insights for rational ligand design targeting the GIPR.
Article
Immunology
Irina Efimova, Inbar Steinberg, Isabel Zvibel, Anat Neumann, Dana Fernanda Mantelmacher, Daniel J. Drucker, Sigal Fishman, Chen Varol
Summary: GIPR plays a significant role in supporting WAT type 2 immunity in myeloid immune cells, and its deficiency affects the type 2 immune networks, particularly in adipose tissue.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Nutrition & Dietetics
Pariyarath Sangeetha Thondre, Ifunanya Achebe, Alistair Sampson, Tyler Maher, Laetitia Guerin-Deremaux, Catherine Lefranc-Millot, Elisabeth Ahlstrom, Helen Lightowler
Summary: The consumption of pea protein reduces postprandial blood sugar levels and stimulates insulin release, showing a dose-response effect in healthy adults and supporting its role in regulating glycemic and insulin responses.
EUROPEAN JOURNAL OF NUTRITION
(2021)
Review
Endocrinology & Metabolism
Sulayman Aslan Lyons, Jacqueline Leah Beaudry
Summary: GLP-1 receptor agonists are a medication alternative to bariatric surgery that can effectively combat metabolic diseases such as obesity and diabetes. Combining these agonists with other hormones has shown to further improve weight loss and metabolic health outcomes.
Article
Endocrinology & Metabolism
Maura Fanti, Amrendra Mishra, Valter D. Longo, Sebastian Brandhorst
Summary: Dietary interventions, such as time-restricted eating, intermittent fasting, and fasting-mimicking diets, have shown potential for weight loss, but long-term efficacy remains uncertain and requires further research to validate.
CURRENT OBESITY REPORTS
(2021)